


ABOUT ENZYCHEM LIFESCIENCES
Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Based on more than two decades of research, we developed our leading candidate EC-18(Mosedipimod), an oral small molecule derived from Sika deer antler, which has shown to be active across a number of different indications.
PLATFORM TECHNOLOGY

EC-18 targets anti-inflammatory
pathway

Broad therapeutic platform
Developing first-in-class small molecules to target
fundamental inflammation pathways
EC-18 PIPELINE
DEVELOPMENT STAGE

CRIOM: Chemoradiation-induced Oral Mucositis
CIN: Chemotherapy-induced Neutropenia
ARS: Acute Radiation Syndrome
COVID-19: Coronavirus Disease-19
ICI: Immune Checkpoint Inhibitors (PD-1, PD-L1)
NASH: Non-alcoholic Steatohepatitis
Press Releases
Enzychem Lifesciences Presenting at Biotech Showcase Digital 2021
ENGLEWOOD CLIFFS, N.J., Jan. 8, 2021 /PRNewswire/ — Enzychem Lifesciences (KOSDAQ: 183490), announced today that Ki Young Sohn, Chief Executive Officer &a
ENZYCHEM LIFESCIENCES SELECTED TO PRESENT AT 2020 RADIATION RESEARCH SOCIETY ANNUAL MEETING
ENGLEWOOD CLIFFS, NEW JERSEY, USA, September 11, 2020 /EINPresswire.com/ — Enzychem Lifesciences (KOSDAQ: 183490) announced it has been selected to present two posters regarding
EC-18 COULD BE SOUTH KOREA’S NEXT GLOBAL BLOCKBUSTER DRUG BY KI YOUNG SOHN, CHAIRMAN OF ENZYCHEM LIFESCIENCES
September 22, 2020 — Enzychem Lifesciences (KOSDAQ: 183490) announced that EC-18 is a prominent candidate to become the next promising blockbuster drug. EC-18 is a safe